Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305124 | 0.84 | TSHR (0.63) | TSHRHSD17B10LMNASMN1; SMN2KMT2A | |
| SCHEMBL11928957 | 0.84 | TDP1 (0.49) | TSHRHSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL13664126 | 0.84 | THRA (0.43) | TSHRSMN1; SMN2KMT2AMEN1GAA | |
| SCHEMBL9049767 | 0.80 | TSHR (0.58) | TSHRHSD17B10LMNASMN1; SMN2NCOA1 | |
| SCHEMBL11929031 | 0.79 | TSHR (0.49) | TSHRHSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL7802388 | 0.78 | TDP1 (0.52) | TSHRHSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL4307561 | 0.77 | LMNA (0.56) | TSHRHSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL21828876 | 0.77 | SMN1; SMN2 (0.50) | TSHRTDP1SMN1; SMN2KMT2AGAA | |
| SCHEMBL17560160 | 0.77 | TSHR (0.71) | TSHRHSD17B10TDP1LMNASMN1; SMN2 | |
| SCHEMBL31634962 | 0.76 | TDP1 (0.48) | TSHRHSD17B10TDP1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614316-B2 | Optically active quaternary ammonium salt having axial asymmetry and process for producing α-amino acid and derivative thereof with the same | NAGASE & CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2484667-A1 | Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same | NAGASE & COMPANY, LTD. (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2484667-A1 | Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same | NAGASE & COMPANY, LTD. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1797049-A4 | 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-17 | — | — | EP | disclosed |
| EP-1870403-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & COMPANY, LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870403-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & COMPANY, LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1797049-A1 | 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006042215-A1 | 1,2,4-TRIAZOLYLAMINOARYL (HETEROARYL) SULFONAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | TSHR 3260/4885HSD17B10 1492/4885TDP1 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.